CTOs on the Move

Dyancon

www.dynacon.ca

 
Dyancon is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.dynacon.ca
  • 3565 Nashua Dr Mississauga ON
    Mississauga, ON CAN L4V 1R1
  • Phone: 866.672.8828

Executives

Name Title Contact Details

Similar Companies

KP Consulting

KP Consulting Inc. is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CerpassRx

CerpassRx is dedicated to giving you the best online pharmacy experience possible. Contact us today to get your pharmacy benefit management.

BeyondSpring

BeyondSpring is a Global, Clinical-Stage. Bio-pharmaceutical Company. Developing Innovative Immuno-Oncology Cancer Therapies with a Robust Pipeline from Internal Development and from Collaboration with University of Washington in De Novo Drug Discovery Using a Ubiquitination Platform.

Sonovion Pharmaceuticals

Sonovion Pharmaceuticals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Windtree Therapeutics

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.